The ACT NOW study examined whether treatment of impaired glucose tolerance in pre-diabetic patients with pioglitazone could prevent or delay the development of type 2 diabetes. Join host Dr. Steven Edelman and his guest, endocrinologist and professor of medicine at the University of California San Diego, Dr. Robert Henry, as they discuss the results and implications for clinical care.
Interventions Targeting Impaired Glucose Tolerance
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Recommended
Details
Presenters
Overview
The ACT NOW study examined whether treatment of impaired glucose tolerance in pre-diabetic patients with pioglitazone could prevent or delay the development of type 2 diabetes. Join host Dr. Steven Edelman and his guest, endocrinologist and professor of medicine at the University of California San Diego, Dr. Robert Henry, as they discuss the results and implications for clinical care.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?